Brain+ nominates an international digital health industry expert and experienced investor profile as new chairman candidate
COMPANY ANNOUNCEMENT
Brain+ A/S (Nasdaq First North: BRAINP) - This information is information that Brain+ A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on February 12, 2024
-
Tim Juergens, who is a strong believer in the potential of digital therapeutics, will be up for election at Brain+’ Annual General Meeting on May 15, 2024, and until then act as active board observer and strategic partner to management
-
In the interim, Johan Luthman, who has been on the company’s board since September 2022, takes the role as chairman
Copenhagen, Denmark, February 12, 2024 – The Board of Directors of Brain+ A/S (“Brain+”) has nominated Tim Juergens as new board member candidate. Tim will be up for election at the company’s Annual General Meeting on May 15, 2024, and is intended thereafter to take over the position as chairman. Tim will succeed Johan Luthman, member of Brain+’ board of directors since September 2022, who covers the position as interim chairman in the transition period from January 31, 2024 and until the Annual General Meeting.
Immediately upon his nomination, Tim Juergens joins the Board of Directors as an active observer and starts to engage operationally with the management team to prepare for his intended role as chairman and assist with fundraising, strategic development and governance work.
Tim Juergens is an experienced healthcare executive with a proven track record also in venture capital and private equity. He is a strong believer in the role and potential of digital health and therapeutic solutions to solve the challenges that are putting global healthcare systems under pressure. Tim has co-founded and manages the digital health-focused venture capital firm, Seedlink SL and holds several board positions in early-stage healthtech companies including as chairman of the Danish digital health company, Hedia, and digital advisory board member of Gerresheimer. In addition, Tim brings to Brain+ 20-years of experience from leading country and commercial roles in the the big pharma companies, Bayer and Roche, with key competences in General Management, Digital Health Solutions, Medical Devices, Sales Effectiveness, Market Access, Validation, and Market Analysis.
Motivating his interest in joining the Board of Directors of Brain+, Tim Juergens, new chairman candidate, commented: “I have followed Brain+ for years and at this point, the company has matured considerably and now stands at the threshold of starting a scaling journey for its first product in the United Kingdom, which is an attractive market for new digital health solutions. The unmet clinical need of dementia is vast and important to address, and the dementia therapeutics of Brain+ are unique and building on the leading non-drug therapy in the field. Based on my experience, I believe Brain+ has real potential for leadership in digital dementia therapy and is maneuvering all the right pieces into position to achieve this. Therefore, I find this part of the company’s journey particularly exciting.”
Kim Baden-Kristensen, CEO and Co-founder of Brain+, commented: “I am extremely pleased that Tim has accepted to join Brain+ as our new chairman of the board. We have been eyeing Tim for several years, and I cannot think of a better profile to optimally grow our company from its current stage of development. His unique blend of competencies and experiences as both a healthcare industry leader and a hands-on digital health venture capitalist, building on extensive pharma and medtech market insights, are key to optimally move our business forward from initial sales to international scale.”
Contact Information
Brain+: CEO and Co-founder, Kim Baden-Kristensen, + 45 31393317, kim@brain-plus.com
Certified Advisor: Keswick Global AG, + 43 1740408045, info@keswickglobal.com
------------------------
Brain+ mission: Bringing effective digitally delivered dementia therapies to those in need, serving a million people with dementia, caregivers and clinicians by 2030.
